⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie

h-index: 8
Total citations: 385
Total papers: 21

Homepage: https://www.uvsq.fr/biomarqueurs-et-essais-cliniques-en-cancerologie-et-onco-hematologie-beccoh-ur-4340

Recent papers from Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie

MEK inhibition achieves robust and durable responses in Erdheim–Chester diseaseHemaSphere · 2026
Prevalence, patterns and outcomes of cardiac involvement in Erdheim–Chester diseaseEuropean Heart Journal · 2022
Role of the Wnt5A pathway in resistance to immune checkpoint inhibitors in advanced Non-Small Cell Lung CancerCancer Immunology Immunotherapy · 2026
From clusters to clinic: an 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancerEuropean Journal of Cancer · 2026
International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic NeoplasmsBlood · 2026
Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study2026
Long-term MAPK inhibition of childhood refractory-Langerhans cell histiocytosis: an observational study on 288 patientsBlood Advances · 2026
Balanoposthitis due to Klebsiella aerogenes in men who have sex with menJournal of the European Academy of Dermatology and Venereology · 2026
Real‐Life Efficacy and Safety of BRAF Inhibitors in Erdheim‐Chester DiseaseAmerican Journal of Hematology · 2025
Suicidal ideation in patients with atopic dermatitis: A case‐control study on 23,191 adultsJournal of the European Academy of Dermatology and Venereology · 2025
International insights into bullying in patients with atopic dermatitis: Global trends and key predictorsJournal of the European Academy of Dermatology and Venereology · 2025
BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Journal of Clinical Oncology · 2025
Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomographyEuropean Journal of Cancer Prevention · 2025
NTRK1-rearranged histiocytosis: clinicopathologic and molecular featuresBlood Advances · 2025
Atopic dermatitis starting in childhood has a stronger impact on adults: results from the ‘Scars of Life’ international project in 27 countriesBritish Journal of Dermatology · 2025
MEK inhibitors are effective in Erdheim–Chester disease regardless of MAPK pathway mutationsLeukemia · 2025
Histiocytoses and reactive proliferations of histiocytes: current state of the art and evolving concepts—a report from the joint CSHP-EA4HP-SH workshop 2024, Hefei, ChinaVirchows Archiv · 2025
Risk of Second Cancer in Erdheim-Chester DiseaseJAMA Oncology · 2025
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France TrialsJournal of Clinical Oncology · 2025
Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosisDiagnostic Pathology · 2025